Evidence map›Paper›PMID 28664363›Full record

Article3 Biotech2017

A novel strain of Aureobasidium sp. TeO12 for theophylline production from caffeine.

Morahem Ashengroph

Open access · bronzeAbstract read
In one paragraph

Article in 3 Biotech, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Morahem AshengrophDepartment of Biological Sciences and Biotechnology, Faculty of Sciences, University of Kurdistan, P.O. Box 416, Sanandaj, Iran. m.ashengroph@uok.ac.ir.ORCID http://orcid.org/0000-0001-6821-0192
University of Kurdistan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A total of 40 fungal cultures were isolated for their ability to grow on caffeine as a sole source carbon and nitrogen, and further screened for theophylline-producing activities under the growing cell system. Based on thin-layer chromatography and high-performance liquid chromatography analyses, the potent strain Aureobasidium sp. TeO12 was chosen for its capability to generate theophylline via biotransformation of caffeine. It was identified based on phenotypic characteristics and its ITS1-5.8S-ITS2 rDNA sequencing data (GenBank accession number no. KT439072). To improve theophylline yield, the effects of various factors, such as resting cell density, Fe(II) concentration, and course of the transformation of caffeine, were studied in a biotransformation reaction containing 0.1 M sodium phosphate buffer (pH 7), Aureobasidium sp. TeO12 resting cells as the whole-cell catalyst and caffeine (2.5 g/L) as the substrate, and the reaction was incubated at 30 °C on an orbital shaker (200 rpm). The results indicated that optimal combination included resting cell density 6 g/L, Fe(II) concentration 75 mg/L, and the biotransformation time 72 h. Under these optimal reaction conditions, the highest theophylline concentration of 1.55 g/L (molar yield of 67%) with an average degradation yield of the substrate of about 83% was obtained in the biotransformation process. This is the first report on the biotransformation of caffeine into theophylline by a novel strain of the genus Aureobasidium.

Indexed as

Aureobasidium sp.BiotransformationCaffeineResting cellTeO12Theophylline

Identifiers

PMID28664363
PMCPMC5491430
OpenAlexW2731642403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.